These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 26121676)

  • 1. Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol.
    Noordman BJ; Shapiro J; Spaander MC; Krishnadath KK; van Laarhoven HW; van Berge Henegouwen MI; Nieuwenhuijzen GA; van Hillegersberg R; Sosef MN; Steyerberg EW; Wijnhoven BP; van Lanschot JJ;
    JMIR Res Protoc; 2015 Jun; 4(2):e79. PubMed ID: 26121676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
    Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
    BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
    Noordman BJ; Spaander MCW; Valkema R; Wijnhoven BPL; van Berge Henegouwen MI; Shapiro J; Biermann K; van der Gaast A; van Hillegersberg R; Hulshof MCCM; Krishnadath KK; Lagarde SM; Nieuwenhuijzen GAP; Oostenbrug LE; Siersema PD; Schoon EJ; Sosef MN; Steyerberg EW; van Lanschot JJB;
    Lancet Oncol; 2018 Jul; 19(7):965-974. PubMed ID: 29861116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial.
    Noordman BJ; Wijnhoven BPL; Lagarde SM; Boonstra JJ; Coene PPLO; Dekker JWT; Doukas M; van der Gaast A; Heisterkamp J; Kouwenhoven EA; Nieuwenhuijzen GAP; Pierie JEN; Rosman C; van Sandick JW; van der Sangen MJC; Sosef MN; Spaander MCW; Valkema R; van der Zaag ES; Steyerberg EW; van Lanschot JJB;
    BMC Cancer; 2018 Feb; 18(1):142. PubMed ID: 29409469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective cohort study on active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer: protocol of Surgery As Needed for Oesophageal cancer-2.
    van der Zijden CJ; Lagarde SM; Hermus M; Kranenburg LW; van Lanschot JJB; Mostert B; Nuyttens JJME; Oudijk L; van der Sluis PC; Spaander MCW; Valkema MJ; Valkema R; Wijnhoven BPL;
    BMC Cancer; 2023 Apr; 23(1):327. PubMed ID: 37038138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.
    Borggreve AS; Mook S; Verheij M; Mul VEM; Bergman JJ; Bartels-Rutten A; Ter Beek LC; Beets-Tan RGH; Bennink RJ; van Berge Henegouwen MI; Brosens LAA; Defize IL; van Dieren JM; Dijkstra H; van Hillegersberg R; Hulshof MC; van Laarhoven HWM; Lam MGEH; van Lier ALHMW; Muijs CT; Nagengast WB; Nederveen AJ; Noordzij W; Plukker JTM; van Rossum PSN; Ruurda JP; van Sandick JW; Weusten BLAM; Voncken FEM; Yakar D; Meijer GJ;
    BMC Cancer; 2018 Oct; 18(1):1006. PubMed ID: 30342494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer.
    Eyck BM; van der Wilk BJ; Noordman BJ; Wijnhoven BPL; Lagarde SM; Hartgrink HH; Coene PPLO; Dekker JWT; Doukas M; van der Gaast A; Heisterkamp J; Kouwenhoven EA; Nieuwenhuijzen GAP; Pierie JEN; Rosman C; van Sandick JW; van der Sangen MJC; Sosef MN; van der Zaag ES; Spaander MCW; Valkema R; Lingsma HF; Steyerberg EW; van Lanschot JJB;
    Trials; 2021 May; 22(1):345. PubMed ID: 34001287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-analysis.
    Eyck BM; Onstenk BD; Noordman BJ; Nieboer D; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
    Ann Surg; 2020 Feb; 271(2):245-256. PubMed ID: 31188203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
    Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
    Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active surveillance in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal or junctional cancer.
    Noordman BJ; Wijnhoven BPL; Lagarde SM; Biermann K; van der Gaast A; Spaander MCW; Valkema R; van Lanschot JJB
    Dis Esophagus; 2017 Dec; 30(12):1-8. PubMed ID: 28881890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 12. Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer: a systematic review and meta-analysis.
    van Rossum PSN; Goense L; Meziani J; Reitsma JB; Siersema PD; Vleggaar FP; van Vulpen M; Meijer GJ; Ruurda JP; van Hillegersberg R
    Gastrointest Endosc; 2016 May; 83(5):866-79. PubMed ID: 26632523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial.
    van der Wilk BJ; Eyck BM; Doukas M; Spaander MCW; Schoon EJ; Krishnadath KK; Oostenbrug LE; Lagarde SM; Wijnhoven BPL; Looijenga LHJ; Biermann K; van Lanschot JJB
    Br J Surg; 2020 Dec; 107(13):1791-1800. PubMed ID: 32757307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endoscopic ultrasound measurements for detection of residual disease after neoadjuvant chemoradiotherapy for esophageal cancer.
    van der Bogt RD; Noordman BJ; Krishnadath KK; Roumans CAM; Schoon EJ; Oostenbrug LE; Siersema PD; Vleggaar FP; van Lanschot JJB; Spaander MCW
    Endoscopy; 2019 Apr; 51(4):326-332. PubMed ID: 30497088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance of Clinically Complete Responders Using Serial
    Valkema MJ; van der Wilk BJ; Eyck BM; Wijnhoven BPL; Spaander MCW; Doukas M; Lagarde SM; Schreurs WMJ; Roef MJ; van Lanschot JJB; Valkema R
    J Nucl Med; 2021 Apr; 62(4):486-492. PubMed ID: 32887759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Surgical Approach on Long-term Survival in Esophageal Adenocarcinoma Patients With or Without Neoadjuvant Chemoradiotherapy.
    Noordman BJ; van Klaveren D; van Berge Henegouwen MI; Wijnhoven BPL; Gisbertz SS; Lagarde SM; van der Gaast A; Hulshof MCCM; Biermann K; Steyerberg EW; van Lanschot JJB;
    Ann Surg; 2018 May; 267(5):892-897. PubMed ID: 28350565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Added value of MRI to endoscopic and endosonographic response assessment after neoadjuvant chemoradiotherapy in oesophageal cancer.
    Vollenbrock SE; van Dieren JM; Voncken FEM; van Turenhout ST; Kodach LL; Hartemink KJ; van Sandick JW; Aleman BMP; Beets-Tan RGH; Bartels-Rutten A
    Eur Radiol; 2020 May; 30(5):2425-2434. PubMed ID: 31965258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
    Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M
    Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
    Goense L; Visser E; Haj Mohammad N; Mook S; Verhoeven RHA; Meijer GJ; van Rossum PSN; Ruurda JP; van Hillegersberg R
    Eur J Surg Oncol; 2018 May; 44(5):620-625. PubMed ID: 29478739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial).
    van Heijl M; Omloo JM; van Berge Henegouwen MI; Busch OR; Tilanus HW; Bossuyt PM; Hoekstra OS; Stoker J; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Bilgen EJ; Ten Kate FJ; Boellaard R; Pruim J; Sloof GW; van Lanschot JJ
    BMC Med Phys; 2008 Jul; 8():3. PubMed ID: 18671847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.